USA:(540) 808-3925
China:400-117-0038
United States
Shopping Cart
Sign in \ Register
RSV604 (CAS: 676128-63-5)
Catalog #:EBC51027
  SKU-Pack Size Availability Size Price
EBC51027-1ML In Stock 1mL(10mM in DMSO) $148.50
EBC51027-2MG In Stock 2mg $88.50
EBC51027-5MG In Stock 5mg $118.50
EBC51027-10MG In Stock 10mg $193.50
EBC51027-50MG In Stock 50mg $748.50
If you want to get a larger packsize, Please contact your local distributor or
email us atinfo@ebiocell.com
Please Select The Country You Are In To Find Your Local Distributor.
EbioCell Phone:(540) 808-3925
Imperial Business Park 4819 Emperor Boulevard, E-mail:order@ebiocell.com
United States Suite 408 Durham, NC 27703, USA Web:www.ebiocell.com
Product Information
Synonym(s) RSV-604,RSV 604
Application RSV604 is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM)
CAS Number 676128-63-5
Purity ≥98.0%
Molecular Weight 388.39
Molecular Formula C₂₂H₁₇FN₄O₂
SMILES C1=CC=C(C=C1)C2=N[C@@H](C(=O)NC3=CC=CC=C32)NC(=O)NC4=CC=CC=C4F
Target & IC50 RSV:EC50 = 0.86 μM
Solubility DMSO: 195 mg/mL (502.07 mM)
Ethanol: 9 mg/mL (23.17 mM)
Preparing Stock Solutions
ConcentrationSolventMass 1 mg 5 mg 10 mg
1 mM 2.5747 ml 12.8737 ml 25.7473 ml
5 mM 0.5149 ml 2.5747 ml 5.1495 ml
10 mM 0.2575 ml 1.2874 ml 2.5747 ml
50 mM 0.0515 ml 0.2575 ml 0.5149 ml
Shipping Gel Pack
Storage Store at -20°C
Research Use For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use.
Product Description

 RSV604 is a novel inhibitor of respiratory syncytial virus replication(EC50=0.86 uM); a putative RSV nucleoprotein(N) inhibitor in phase 2 clinical trials.IC50 value: 0.86 uM(EC50) It proved to be equipotent against all clinical isolates tested of both the A and B subtypes of the virus. The compound has a low rate of in vitro resistance development. Sequencing revealed that the resistant virus had mutations within the nucleocapsid protein. This is a novel mechanism of action for anti-RSV compounds. In a three-dimensional human airway epithelial cell model, RSV604 was able to pass from the basolateral side of the epithelium effectively to inhibit virus replication after mucosal inoculation. RSV604, which is currently in phase II clinical trials, represents the first in a new class of RSV inhibitors and may have significant potential for the effective treatment of RSV disease.

Specific Protocols
>> Western Blotting Protocol >> Immunoprecipitation Protocol
>> Immunohistochemistry Protocol >> Immunofluorescence Protocol
>> Immunocytochemistry Protocol >> Flow Cytometry Protocol
>> ChIP Protocol >> ELISA Protocol
>> HPLC Protocol >> PCR Protocol
For Research Use Only, Not For Diagnostic Or Therapeutic Procedures.
Copyright 2015 EbioCell, Inc. All Rights Reserved.  备案号:津ICP备2022005142号-1